Evidence map›Paper›PMID 41843267›Full record

GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).

Virginia Arrazubi, Lara Iglesias, Marc Oliva, Pedro Pérez Segura, Jordi Rubió-Casadevall, Gemma Bruixola, Alberto Carral, Beatriz Castelo, Beatriz Cirauqui, Antonio Rueda

Abstract readPractice GuidelineReview
In one paragraph

Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Virginia ArrazubiMedical Oncology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. varrazubi@gmail.com.ORCID http://orcid.org/0000-0002-1431-2780
Lara IglesiasMedical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Marc OlivaMedical Oncology Department, Institutd'InvestigacióBiomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia (ICO) L'Hospitalet, Barcelona, Spain.
Pedro Pérez SeguraMedical Oncology Department, Hospital Clínico San Carlos, IdISC (Instituto de Investigación del Hospital Clínico San Carlos), Madrid, Spain.
Jordi Rubió-CasadevallMedical Oncology Department. Catalan Institute of Oncology, Hospital Josep Trueta, Oncogirpro Group, Biomedical Research Institute of Girona (IDIBGI), Girona, Spain.
Gemma BruixolaMedical Oncology Department, Hospital Clinico Universitario de Valencia-INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
Alberto CarralMedical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain.
Beatriz CasteloMedical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
Beatriz CirauquiMedical Oncology Department, Catalan Institute of Oncology (ICO), Badalona, Spain.
Antonio RuedaMedical Oncology Department, Hospital Universitario Virgen de La Victoria, Málaga, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality approaches. In the case of recurrent or metastatic disease, curative intent should be considered for patients with local recurrence or oligometastatic disease, while systemic treatment is recommended for all other cases. These guidelines, developed by the authors on behalf of the Spanish Society of Medical Oncology (SEOM) and the Spanish Group for the Treatment of Head and Neck Tumors (TTCC), review available evidence and provide expert recommendations based on the current literature.

Indexed as

Head and Neck NeoplasmsCombined Modality TherapyHumansMedical OncologySpainChemoradiotherapyGuidelinesHead and neck cancerImmunotherapy

Identifiers

PMID41843267
PMCPMC13186868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.